Canaccord analyst Jason Mills maintained a Buy rating on Edwards Lifesciences (EW) and raised his price target to $215 from $190 after the PARTNER 3 trial delivered superiority to surgery. In a research note to investors, Mills says he thinks the data will give Edwards a definitive marketing advantage in the TAVRmarket, relative to both Medtronic (MDT) and Boston Scientific (BSX), he thinks now has a higher hurdle to clear in TAVR than pre-Phase 3 data release.
https://thefly.com/landingPageNews.php?id=2880379
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.